VEGFA and retinopathy of prematurity: Thus, we suggest H2 as an alternative or additional strategy to overcome the side effects of VEGF-A blockade for the treatment of ischemic retinopathies such as ROP, PDR, and retinal vascular occlusive diseases, even intervention at an early stage.